Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of Sparsentan Oral Suspension
NCT05562362Phase 1Completed
- Sponsor
- Travere Therapeutics
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by Travere Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration (Single Dose) at Day 8, Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration (Single Dose) at Day 8 and 7 more. Started Jun 2020; status: completed.
02
Drugs
sparsentan
03
Conditions
IgA nephropathy (IgAN)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05562362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562362.